SynBiotic SE - Asset Resilience Ratio
SynBiotic SE (SBX) has an Asset Resilience Ratio of 5.09% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does SynBiotic SE carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how SynBiotic SE's Asset Resilience Ratio has changed over time. See SBX net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down SynBiotic SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SBX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.07 Million | 5.09% |
| Total Liquid Assets | €2.07 Million | 5.09% |
Asset Resilience Insights
- Limited Liquidity: SynBiotic SE maintains only 5.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SynBiotic SE Industry Peers by Asset Resilience Ratio
Compare SynBiotic SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 6.43% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 6.40% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for SynBiotic SE (2020–2023)
The table below shows the annual Asset Resilience Ratio data for SynBiotic SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 7.75% | €2.71 Million ≈ $3.16 Million |
€34.92 Million ≈ $40.82 Million |
+2.66pp |
| 2022-12-31 | 5.09% | €2.07 Million ≈ $2.42 Million |
€40.62 Million ≈ $47.49 Million |
+1.73pp |
| 2021-12-31 | 3.36% | €2.04 Million ≈ $2.38 Million |
€60.65 Million ≈ $70.90 Million |
+3.21pp |
| 2020-12-31 | 0.15% | €52.14K ≈ $60.95K |
€35.03 Million ≈ $40.95 Million |
-- |
About SynBiotic SE
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. T… Read more